Amniotic cell therapy - NuCel

Drug Profile

Amniotic cell therapy - NuCel

Alternative Names: Human amniotic allograft; NuCel; ReNu™

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator NuCel
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone disorders
  • Phase II Intervertebral disc degeneration

Most Recent Events

  • 01 Dec 2016 NuTech Medical terminates a phase II trial in Intervertebral disc degeneration in USA due to departure of PI from the study facility (NCT02381067)
  • 21 Feb 2014 OhioHealth & NuCel initiate enrolment in a phase II trial for Intervertebral disc degeneration in USA (NCT02070484)
  • 27 Dec 2013 Phase-II clinical trials in Intervertebral disc degeneration in USA (Intralumbar)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top